BCRX vs. JAZZ

Last updated Apr 2, 2026

Compare and contrast key facts about BioCryst Pharmaceuticals, Inc. (BCRX) and Jazz Pharmaceuticals plc (JAZZ).

Performance

BCRX vs. JAZZ - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BioCryst Pharmaceuticals, Inc. (BCRX) and Jazz Pharmaceuticals plc (JAZZ). The values are adjusted to include any dividend payments, if applicable.

BCRX vs. JAZZ - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
BCRX BioCryst Pharmaceuticals, Inc.	20.26%	3.72%	25.54%	-47.82%	-17.11%	85.91%	115.94%	-57.25%	64.36%	-22.43%
JAZZ Jazz Pharmaceuticals plc	10.75%	38.04%	0.12%	-22.79%	25.05%	-22.81%	10.56%	20.43%	-7.94%	23.50%

Fundamentals

Market Cap BCRX : $2.06B JAZZ : $11.48B
EPS BCRX : $1.20 JAZZ : -$5.81
PS Ratio BCRX : 2.36 JAZZ : 2.70
Total Revenue (TTM) BCRX : $874.84M JAZZ : $4.27B
Gross Profit (TTM) BCRX : $855.43M JAZZ : $5.11B
EBITDA (TTM) BCRX : $345.49M JAZZ : $835.63M

Returns By Period

In the year-to-date period, BCRX achieves a 20.26% return, which is significantly higher than JAZZ's 10.75% return. Over the past 10 years, BCRX has outperformed JAZZ with an annualized return of 12.73%, while JAZZ has yielded a comparatively lower 3.47% annualized return.

BCRX

• 1D: -1.47%
• 1M: 8.69%
• YTD: 20.26%
• 6M: 27.27%
• 1Y: 29.38%
• 3Y*: 3.99%
• 5Y*: -1.17%
• 10Y*: 12.73%

JAZZ

• 1D: -0.41%
• 1M: -1.15%
• YTD: 10.75%
• 6M: 37.52%
• 1Y: 50.63%
• 3Y*: 8.76%
• 5Y*: 2.65%
• 10Y*: 3.47%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BCRX vs. JAZZ — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BCRX

BCRX Risk / Return Rank: 57
BCRX Sharpe Ratio Rank: 61
BCRX Sortino Ratio Rank: 63
BCRX Omega Ratio Rank: 58
BCRX Calmar Ratio Rank: 54
BCRX Martin Ratio Rank: 51

JAZZ

JAZZ Risk / Return Rank: 78
JAZZ Sharpe Ratio Rank: 79
JAZZ Sortino Ratio Rank: 77
JAZZ Omega Ratio Rank: 78
JAZZ Calmar Ratio Rank: 79
JAZZ Martin Ratio Rank: 78

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BCRX vs. JAZZ - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BioCryst Pharmaceuticals, Inc. (BCRX) and Jazz Pharmaceuticals plc (JAZZ). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BCRX	JAZZ	Difference
Sharpe ratio Return per unit of total volatility	0.58	1.23	-0.65
Sortino ratio Return per unit of downside risk	1.36	2.01	-0.65
Omega ratio Gain probability vs. loss probability	1.15	1.28	-0.12
Calmar ratio Return relative to maximum drawdown	0.57	2.28	-1.71
Martin ratio Return relative to average drawdown	0.91	5.53	-4.61
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BCRX vs. JAZZ - Sharpe Ratio Comparison

The current BCRX Sharpe Ratio is 0.58, which is lower than the JAZZ Sharpe Ratio of 1.23. The chart below compares the historical Sharpe Ratios of BCRX and JAZZ, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	BCRX	JAZZ	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.58	1.23	-0.65
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.02	0.08	-0.10
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.18	0.11	+0.07
Sharpe Ratio (All Time) Calculated using the full available price history	0.01	0.17	-0.16

Correlation

The correlation between BCRX and JAZZ is 0.28, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

BCRX vs. JAZZ - Dividend Comparison

Neither BCRX nor JAZZ has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

BCRX vs. JAZZ - Drawdown Comparison

The maximum BCRX drawdown since its inception was -97.74%, roughly equal to the maximum JAZZ drawdown of -96.90%. Use the drawdown chart below to compare losses from any high point for BCRX and JAZZ.

Drawdown Indicators

	BCRX	JAZZ	Difference
Max Drawdown Largest peak-to-trough decline	-97.74%	-96.90%	-0.84%
Max Drawdown (1Y) Largest decline over 1 year	-44.24%	-22.67%	-21.57%
Max Drawdown (5Y) Largest decline over 5 years	-79.10%	-47.55%	-31.55%
Max Drawdown (10Y) Largest decline over 10 years	-83.69%	-52.10%	-31.59%
Current Drawdown Current decline from peak	-71.69%	-4.35%	-67.34%
Average Drawdown Average peak-to-trough decline	-69.63%	-27.65%	-41.98%
Ulcer Index Depth and duration of drawdowns from previous peaks	27.46%	9.34%	+18.12%

Volatility

BCRX vs. JAZZ - Volatility Comparison

BioCryst Pharmaceuticals, Inc. (BCRX) has a higher volatility of 16.04% compared to Jazz Pharmaceuticals plc (JAZZ) at 7.72%. This indicates that BCRX's price experiences larger fluctuations and is considered to be riskier than JAZZ based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BCRX	JAZZ	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.04%	7.72%	+8.32%
Volatility (6M) Calculated over the trailing 6-month period	34.26%	29.45%	+4.81%
Volatility (1Y) Calculated over the trailing 1-year period	50.62%	41.23%	+9.39%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	63.41%	31.51%	+31.90%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	72.93%	32.72%	+40.21%

Financials